<DOC>
	<DOCNO>NCT00880867</DOCNO>
	<brief_summary>The primary objective study evaluate safety intratumoral Polyinosinicpolycytidylic acid stabilize polylysine carboxymethylcellulose ( poly-ICLC ) ( Hiltonol® ) addition low-dose local radiotherapy adult patient low grade lymphoma , include follicular lymphoma , marginal zone lymphoma , small lymphocytic lymphoma , chronic lymphocytic leukemia , cutaneous T-cell lymphoma . The secondary endpoint response rate , immune response , durability response well generation antiinflammatory response sit tumor involvement .</brief_summary>
	<brief_title>Intratumoral Poly-ICLC Plus Low Dose Local Radiation Low Grade Recurrent B T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>1 . Patients must least 18 year age . 2 . Patients must biopsy confirm lowgrade Bcell lymphoma ( follicular , marginal zone , small cell/chronic lymphocytic leukemia ) mycosis fungoides . Bcell lymphoma patient must fail least one prior therapy ( chemotherapy immunotherapy ) mycosis fungoides patient fail least 1 topical systemic treatment . 3 . Patients must least one accessible tumor site inject polyICLC . 4 . Patients must measurable disease injection site . 5 . Patients must Karnofsky performance status least 70 % . 6 . Patients must adequate hematologic , renal liver function ( i.e. , absolute neutrophil count least 1500/mm3 , Platelets least 100,000/mm3 , creatinine 1.7 mg/dl , total bilirubin 1.5 mg/dl , transaminases 4 time upper limit institutional normal ) . 7 . Patients must able provide write informed consent . 8 . Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Women childbearing potential must negative pregnancy test . While animal test negative , antiproliferative activity experimental drug may theoretically harmful develop fetus nursing infant . 9 . Required washout period prior therapy : Topical therapy : 2 week . Chemotherapy : 4 week Radiotherapy : ( include phototherapy ) : 4 week 13 26 Biological therapy : 4 week Other investigational therapy : 4 week Rituximab : 12 week 1 . Any history autoimmune antibody mediate disease include : systemic lupus , erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia , autoimmune hemolytic anemia , pure red cell aplasia , exclude control thyroid disease , presence autoantibody without clinical autoimmune disease . 2 . Off nucleoside bendustine therapy minimum 6 month 3 . Prior treatment Campath 4 . Known history human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C ( active , prior treatment , ) . 5 . Patients active infection fever &gt; 38.5°C within three day prior first schedule treatment . 6 . CNS metastases . 7 . Prior malignancy ( active within 5 year screen ) except basal cell completely excise noninvasive squamous cell carcinoma skin , situ squamous cell carcinoma cervix . 8 . Current anticoagulant therapy ( ASA 325 mg/day allow ) . 9 . Significant cardiovascular disease ( i.e. , NYHA class 3 congestive heart failure ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia ) . 10 . Pregnant lactating . 11 . Any medical history , include laboratory result , deem investigator likely interfere participation study , interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Low Grade Recurrent B T Cell Lymphoma</keyword>
</DOC>